Skip to content
CompoundSci
All peptides
Research vial labelled CJC-1295 + Ipamorelin, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

CJC-1295 + Ipamorelin

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
100 mcg + 100 mcg
Frequency in protocols
1–3× daily, fasted
Route
Subcutaneous
Half life
~30 minutes (pulsatile)
Reconstitution
2 mL bacteriostatic water per 10 mg blend vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the bedtime window, fasted

One to three times daily, fasted

Same reasoning as tesamorelin: the natural nocturnal growth-hormone pulse is the target, and insulin from a recent meal suppresses it.

Reported cycle: 12 weeks on, 4 weeks off

Growth hormone axis protocols use three month blocks then a break so the pituitary is not being pushed continuously.

Watch for: Water retention, numb or tingling hands, appetite spikes from the ghrelin side, and fasting glucose.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    CJC-1295 + Ipamorelin + Tesamorelin

    Do not run on the same day

    Both drive the same growth-hormone axis. Stacking them does not double the pulse, it flattens it: continuous stimulation of GHRH and ghrelin receptors promotes desensitisation, and the reported side effect load (water retention, carpal tunnel symptoms, insulin resistance) rises with total exposure. Pick one.

  • Hard stopTiming

    CJC-1295 + Ipamorelin + Ipamorelin

    Duplicate ingredient

    The blend already contains ipamorelin. Adding standalone ipamorelin on top is a straightforward double dose of the same secretagogue.

  • Pick oneRedundant, pick one

    CJC-1295 + Ipamorelin + Ipamorelin

    Same target hit twice

    The blend already contains ipamorelin. Adding more is receptor competition, not a cleaner pulse.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how CJC-1295 + Ipamorelin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature